VIR
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Vir Biotechnology completed its global strategic collaboration with Astellas for prostate cancer treatmentApr 17, 2026
- Vir Biotechnology dosed the first patient in Phase 1 expansion cohorts of VIR-5500 for metastatic prostate cancerApr 13, 2026
- Vir Biotechnology reports updated positive Phase 1 data for VIR-5500, a PSMA-targeting PRO-XTEN® dual-masked T-cell engager, in metastatic prostate cancerFeb 24, 2026
- Vir Biotechnology announces AASLD The Liver Meeting® presentation & New England Journal of Medicine publication of Phase 2 data demonstrating Tobevibart & Elebsiran combination deliver high rates of undetectable HDV RNA with favorable safety profileNov 10, 2025
- Vir Biotechnology announces completion of enrollment in ECLIPSE 1 Phase 3 trial for chronic hepatitis deltaNov 3, 2025